Metronomic Oral Vinorelbine in Advanced Breast Cancer and Non-Small-Cell Lung Cancer: Current Status and Future DevelopmentMarina Elena Cazzaniga, Guido Bocci, Andrea Camerini et al.|Future Oncology|2015Cited by 54
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, <i>ERBB2</i>-Negative Metastatic Breast CancerElisabetta Munzone, L. J. Blacher, Elisabetta Cretella et al.|JAMA Oncology|2023Cited by 37
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO StudyNicla La Verde, Sandro Barni, Elena Collovà et al.|Clinical Breast Cancer|2020Cited by 17
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA studyChiara Molinelli, Lucia Del Mastro, Marco Bruzzone et al.|European Journal of Cancer|2024Cited by 15
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II studyRoberta Caputo, Michelino De Laurentiis, Marina Elena Cazzaniga et al.|BMC Cancer|2020Cited by 12